'indian ip and liabilities law barrier to pharma r&d investment'
.
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
us opioid crisis hits indian pharma companies
.
�such figures underline how vital it is that the government supports the nhs to improve waiting times this year.�
.
.
.
.
.